Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCGNJ6)

Drug Name
CDX-1401 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMCGNJ6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cancer/testis antigen 1 (NY-ESO-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [4]
Anti-NY-ESO-1 CAR-T cells DM26VCZ Esophageal cancer 2B70 Phase 1/2 [5]
NY-ESO-1 vaccine DM0EKUQ Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
GSK-2241658A DM5VS7B Melanoma 2C30 Phase 1 [7]
GSK3901961 DMN4I7P Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
GSK3845097 DM1UQ4Y Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
Melanoma vaccine (ALVAC) DM3HIQY Melanoma 2C30 Discontinued in Phase 2 [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cancer/testis antigen 1 (NY-ESO-1) TTE5ITK CTG1B_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02129075) CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma. U.S. National Institutes of Health.
3 National Cancer Institute Drug Dictionary (drug id 651880).
4 National Cancer Institute Drug Dictionary (drug id 648549).
5 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
6 Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
7 ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of GlaxoSmithKline.
9 Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.